Halozyme Therapeutics, Inc. $HALO Shares Acquired by Advantage Alpha Capital Partners LP

Key Points

• Advantage Alpha Capital Partners LP has increased its stake in Halozyme Therapeutics by 53.1% in the first quarter, acquiring an additional 4,797 shares, bringing its total to 13,830 shares valued at $882,000.
• Halozyme Therapeutics reported a strong quarterly earnings performance with an EPS of $1.54, surpassing estimates by $0.31, and achieving revenues of $325.72 million, a 40.8% increase year over year.
• Analysts have varied opinions on Halozyme Therapeutics, with ratings ranging from a "strong sell" to a "strong buy," and an average price target set at $67.11.

Advantage Alpha Capital Partners LP grew its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 53.1% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 13,830 shares of the biopharmaceutical company's stock after buying an additional 4,797 shares during the period. Advantage Alpha Capital Partners LP's holdings in Halozyme Therapeutics were worth $882,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Penserra Capital Management LLC acquired a new position in shares of Halozyme Therapeutics in the 1st quarter valued at $125,000. Bessemer Group Inc. boosted its holdings in shares of Halozyme Therapeutics by 62.9% in the 1st quarter. Bessemer Group Inc. now owns 536 shares of the biopharmaceutical company's stock valued at $34,000 after buying an additional 207 shares in the last quarter. D. E. Shaw & Co. Inc. boosted its holdings in shares of Halozyme Therapeutics by 171.2% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 831,414 shares of the biopharmaceutical company's stock valued at $39,750,000 after buying an additional 524,802 shares in the last quarter. Fifth Third Bancorp boosted its holdings in shares of Halozyme Therapeutics by 29.4% in the 1st quarter. Fifth Third Bancorp now owns 10,017 shares of the biopharmaceutical company's stock valued at $639,000 after buying an additional 2,276 shares in the last quarter. Finally, GAMMA Investing LLC boosted its stake in Halozyme Therapeutics by 199.0% during the 1st quarter. GAMMA Investing LLC now owns 2,802 shares of the biopharmaceutical company's stock worth $179,000 after purchasing an additional 1,865 shares during the period. Institutional investors and hedge funds own 97.79% of the company's stock.

Halozyme Therapeutics Stock Performance

Shares of HALO opened at $71.61 on Friday. The company has a 50-day simple moving average of $58.36 and a 200-day simple moving average of $58.64. The company has a quick ratio of 7.01, a current ratio of 8.36 and a debt-to-equity ratio of 4.54. The company has a market capitalization of $8.38 billion, a PE ratio of 16.39, a P/E/G ratio of 0.40 and a beta of 1.17. Halozyme Therapeutics, Inc. has a 52-week low of $42.01 and a 52-week high of $72.33.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $1.54 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.23 by $0.31. The business had revenue of $325.72 million during the quarter, compared to the consensus estimate of $282.66 million. Halozyme Therapeutics had a net margin of 47.28% and a return on equity of 150.85%. The business's revenue was up 40.8% compared to the same quarter last year. During the same quarter last year, the firm posted $0.91 EPS. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS. Equities research analysts predict that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Halozyme Therapeutics news, CEO Helen Torley sold 20,000 shares of the firm's stock in a transaction dated Tuesday, August 12th. The shares were sold at an average price of $63.51, for a total transaction of $1,270,200.00. Following the completion of the transaction, the chief executive officer directly owned 733,719 shares in the company, valued at approximately $46,598,493.69. This trade represents a 2.65% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In the last ninety days, insiders have sold 80,000 shares of company stock worth $4,532,600. Company insiders own 2.40% of the company's stock.

Analysts Set New Price Targets

A number of analysts recently weighed in on HALO shares. Leerink Partnrs cut shares of Halozyme Therapeutics from a "hold" rating to a "strong sell" rating in a research note on Tuesday, May 13th. Benchmark cut shares of Halozyme Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, May 7th. Morgan Stanley increased their price target on shares of Halozyme Therapeutics from $75.00 to $80.00 and gave the stock an "overweight" rating in a research note on Monday. The Goldman Sachs Group started coverage on shares of Halozyme Therapeutics in a research note on Thursday, July 10th. They set a "neutral" rating and a $55.00 price target for the company. Finally, Leerink Partners cut shares of Halozyme Therapeutics from a "market perform" rating to an "underperform" rating and set a $47.00 price target for the company. in a research note on Tuesday, May 13th. Four investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have issued a Sell rating to the company's stock. According to MarketBeat.com, Halozyme Therapeutics currently has an average rating of "Hold" and a consensus price target of $67.11.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.